- Published on
Ophthalmology – Coloboma (Eyelid, Iris, Optic Nerve, Retina)
Coloboma is a congenital developmental abnormality resulting from incomplete closure of the embryonic (choroidal) fissure during the fifth week of gestation. The term originates from the Greek word meaning “curtailed” or “mutilated.” It presents as a defect or gap in ocular structures, which may involve the eyelid, iris, retina, choroid, or optic nerve. These defects are typically located inferiorly due to the inferonasal position of the embryonic fissure during development.
The incidence of coloboma is approximately 0.5–0.7 per 10,000 births. It can occur unilaterally or bilaterally with roughly equal frequency. Most cases are sporadic, though inherited forms exist, including autosomal dominant and recessive patterns. Mutations in the PAX2 gene have been identified in a significant proportion of cases and are associated with abnormalities in organs such as the kidney, central nervous system, and ear.
The pathophysiology involves incomplete or abnormal fusion of the embryonic fissure, resulting in absence or maldevelopment of structures such as the iris, retina, and choroid. The extent and location of the defect determine clinical severity and associated complications.
Coloboma is frequently associated with systemic syndromes. Eyelid colobomas may occur in conditions like Treacher Collins syndrome or Goldenhar syndrome. Optic nerve and iris colobomas can be linked to systemic conditions such as Patau syndrome, renal coloboma syndrome, or basal encephalocele. Chorioretinal colobomas are commonly associated with CHARGE syndrome and other multisystem disorders.
Clinical presentation varies widely. Many patients are asymptomatic unless critical structures such as the macula or optic nerve are involved. Eyelid colobomas may lead to exposure-related dry eye. Iris colobomas typically present as an inferonasal “keyhole” pupil and may cause photophobia. Optic nerve colobomas may present with reduced vision, nystagmus, refractive error, or leukocoria. Chorioretinal colobomas appear as well-demarcated white areas in the inferior fundus and may be associated with visual field defects or retinal detachment.
Diagnosis is primarily clinical, based on slit-lamp examination and fundus evaluation. Imaging may be required depending on the subtype. CT or MRI can help assess associated craniofacial or intracranial abnormalities, especially in syndromic cases. B-scan ultrasonography may be used to detect associated cysts or posterior segment abnormalities. Additional investigations such as chromosomal analysis or renal ultrasound may be indicated when systemic involvement is suspected.
Management is largely supportive, as there is no direct treatment for the structural defect. Visual rehabilitation is key and includes correction of refractive error, amblyopia therapy (especially in children), and use of tinted lenses or cosmetic contact lenses for iris defects. Patients with microphthalmia may benefit from scleral shells or orbital expanders.
Surgical intervention is reserved for complications. Strabismus surgery may be performed if ocular misalignment is present. Retinal detachment associated with chorioretinal coloboma requires prompt surgical management, often including laser photocoagulation around the margins of the defect.
Regular follow-up with an ophthalmologist is essential, along with systemic evaluation by pediatricians or internists when syndromic associations are present. Monitoring focuses on visual development, refractive changes, and early detection of complications such as retinal detachment.
The prognosis depends on the size and location of the coloboma. Isolated iris colobomas generally have excellent visual outcomes, whereas optic nerve or extensive chorioretinal colobomas may result in significant and unpredictable visual impairment.
Complications include amblyopia, refractive errors, glaucoma, retinal detachment, and, less commonly, choroidal neovascularization.
- Published on
Ophthalmology – Coloboma
Coloboma is a congenital ocular defect characterized by a cleft or gap in ocular structures due to incomplete closure of the embryonic (choroidal) fissure during early fetal development. It may affect the iris, retina, choroid, or optic nerve, and is typically located in the inferonasal quadrant. Coloboma can occur unilaterally or bilaterally and may be isolated or associated with other ocular or systemic abnormalities.
The condition is relatively uncommon, with an estimated incidence of approximately 2.6 per 10,000 births in the United States. While some cases occur in isolation, a significant proportion are associated with other congenital anomalies or syndromes, particularly CHARGE syndrome, which is one of the most frequently linked multisystem conditions.
Risk factors include genetic mutations, chromosomal abnormalities, and environmental influences during pregnancy. Several genes have been implicated, including PAX6, SHH, and CHD7. Coloboma is also associated with Microphthalmia, and potential environmental contributors include teratogens such as alcohol or thalidomide, as well as vitamin A deficiency during pregnancy. Inheritance patterns vary and may be sporadic, autosomal dominant, autosomal recessive, or X-linked.
The underlying pathophysiology involves failure of closure of the fetal fissure between the 5th and 7th weeks of gestation. This results in defective development of the retinal pigment epithelium, abnormal choroidal formation, and dysplastic overlying retina. The timing and extent of this developmental failure influence both the severity of the ocular defect and the likelihood of associated systemic anomalies.
Clinically, presentation depends on the structures involved. Iris coloboma appears as a characteristic “keyhole” pupil, usually inferonasally. Posterior segment involvement, such as chorioretinal coloboma, presents as a sharply demarcated white excavation in the fundus, sometimes with visible retinal vessels traversing the defect. Visual symptoms may include decreased vision, visual field defects (typically superior scotoma), strabismus, or nystagmus. Some patients may present with leukocoria.
A comprehensive examination is essential, including visual acuity testing, slit-lamp evaluation, and dilated fundus examination. Assessment for amblyopia, refractive error, and retinal detachment is critical. Family members may also require examination, as some cases are asymptomatic but hereditary. Systemic evaluation is important to identify associated anomalies.
Diagnostic investigations may include ocular ultrasound to assess for associated cysts or microphthalmia, and brain MRI if optic nerve involvement or central nervous system abnormalities are suspected. Genetic testing and counseling are recommended, particularly in syndromic or familial cases. Additional systemic investigations such as echocardiography or audiology testing may be indicated depending on associated findings.
Management focuses on maximizing visual potential and monitoring for complications, as there is no direct treatment for the structural defect itself. Amblyopia therapy is often required in children. Patients with significant visual impairment may benefit from low vision rehabilitation. Referral to genetics and pediatric specialists is appropriate when systemic associations are present.
Surgical intervention may be necessary for complications such as retinal detachment, cataract, or strabismus. In severe cases with microphthalmia, ocular prosthetic support may be considered for cosmetic and structural purposes.
Regular follow-up is essential, particularly to monitor for retinal detachment, which is a known complication. Visual development, educational progress, and systemic health should also be monitored over time.
The prognosis varies widely depending on the size and location of the defect. Small anterior colobomas may have minimal visual impact, whereas large posterior colobomas involving the macula or optic nerve can result in significant visual impairment. Associated systemic abnormalities further influence overall outcomes.
- Published on
Ophthalmology – Clinically Significant Diabetic Macular Edema (CSME)
Clinically significant diabetic macular edema (CSME) is a vision-threatening form of diabetic macular edema defined by the Early Treatment Diabetic Retinopathy Study (ETDRS). It is present when there is retinal thickening within 500 microns of the center of the fovea, hard exudates within 500 microns of the foveal center with adjacent retinal thickening, or an area of retinal thickening at least one disc area in size with any part located within one disc diameter of the foveal center. CSME may be focal, resulting from leakage from isolated microaneurysms, or diffuse, due to generalized breakdown of the inner blood-retinal barrier.
CSME is the leading cause of visual loss in patients with diabetes. Its frequency increases with longer duration of diabetes and with more severe diabetic retinopathy. Studies have shown that a substantial proportion of both type 1 and type 2 diabetic patients develop CSME over time, and hundreds of thousands of individuals are affected in the United States alone.
Major risk factors include long-standing diabetes, poor glycemic control, hypertension, hyperlipidemia, nephropathy, proteinuria, and more advanced diabetic retinopathy. In patients with adult-onset diabetes, insulin use has also been associated with higher risk. Pregnancy can accelerate diabetic retinopathy and CSME, so careful ophthalmic monitoring is recommended before and throughout pregnancy.
The pathophysiology of CSME reflects chronic hyperglycemia-induced damage to the retinal microvasculature. This includes pericyte loss, thickening of the capillary basement membrane, endothelial dysfunction, leukostasis, oxidative stress, and increased inflammatory cytokines such as VEGF. These changes lead to breakdown of the blood-retinal barrier and leakage of fluid into the macula. In some cases, vitreomacular traction may also contribute to edema formation.
Patients may not always notice symptoms early, but a careful history should assess diabetes duration and control, insulin dependence, hypertension, lipid disorders, and kidney disease. Clinically, CSME is diagnosed by slit-lamp biomicroscopy, sometimes aided by contact lens examination, which demonstrates retinal thickening in the macular area. The severity of diabetic retinopathy and the presence of vitreomacular interface abnormalities should also be documented.
Ancillary testing is helpful for both evaluation and follow-up. Fluorescein angiography is not necessary to make the diagnosis, but it can identify leaking microaneurysms, diffuse leakage, areas of macular ischemia, and capillary nonperfusion. Optical coherence tomography (OCT) is especially valuable for documenting retinal thickening, identifying epiretinal membranes or vitreomacular traction, and monitoring treatment response. Systemic evaluation should include HbA1c, blood pressure, blood lipids, and renal function.
Treatment begins with optimization of systemic disease, including strict control of blood glucose, blood pressure, and lipids. Traditionally, focal laser photocoagulation has been the first-line ocular treatment and has been shown to reduce the risk of visual loss substantially. More recently, intravitreal anti-VEGF agents such as ranibizumab and bevacizumab have become important options and may be superior to laser alone in many cases. Intravitreal corticosteroids can also be useful, especially in selected patients, though they are generally considered adjunctive therapy.
In cases of diffuse CSME, refractory edema, or associated vitreomacular traction, referral to a vitreoretinal specialist is appropriate. Vitrectomy with membrane peeling may benefit patients with persistent edema related to traction or epiretinal membrane formation. Fenofibrate may also reduce the need for laser in some diabetic patients.
Close follow-up is essential because CSME is often chronic and recurrent. Patients undergoing active treatment are commonly reviewed every 1 to 3 months, and those with severe nonproliferative or proliferative diabetic retinopathy generally require dilated examination every 3 to 4 months. Coordination with the patient’s primary care physician or endocrinologist is an important part of management.
The prognosis depends on the duration and severity of edema, associated retinal ischemia, and response to treatment. Without treatment, many patients experience moderate visual loss over time. Laser therapy significantly lowers this risk, and newer therapies may further improve outcomes.
- Published on
Ophthalmology – Chronic Progressive External Ophthalmoplegia (CPEO)
Chronic Progressive External Ophthalmoplegia (CPEO) is a clinical manifestation of mitochondrial cytopathies, a group of disorders caused by dysfunction of mitochondria due to mutations in either mitochondrial DNA or nuclear genes encoding mitochondrial components. It is not a single disease entity but rather a phenotype that can occur within a spectrum of systemic mitochondrial disorders affecting high-energy tissues such as muscle, brain, and heart. A notable associated condition is Kearns–Sayre syndrome (KSS), which includes CPEO, pigmentary retinopathy, and systemic features such as cardiac conduction defects and endocrine abnormalities.
Epidemiologically, CPEO most commonly presents in childhood or early adolescence, although onset can occur at any age. Most cases are sporadic due to single large-scale mitochondrial DNA deletions arising during oocyte development. Less commonly, inherited forms follow autosomal dominant or recessive patterns involving nuclear genes such as POLG or Twinkle. A key concept in mitochondrial disease is heteroplasmy, where varying proportions of normal and mutated mitochondrial DNA determine disease expression once a threshold is exceeded in energy-dependent tissues.
The pathophysiology centers on impaired mitochondrial oxidative phosphorylation, leading to decreased ATP production and dysfunction of cellular processes such as apoptosis regulation, reactive oxygen species detoxification, and metabolic pathways. Extraocular muscles are particularly vulnerable due to their high metabolic demand, explaining the prominent ophthalmic manifestations.
Clinically, patients present with slowly progressive bilateral ptosis and symmetric limitation of eye movements (ophthalmoplegia), typically sparing the pupils. Other systemic features may include limb weakness, hearing loss, ataxia, short stature, seizures, and endocrine abnormalities. In Kearns–Sayre syndrome, a characteristic “salt-and-pepper” pigmentary retinopathy may be observed. Importantly, cardiac conduction abnormalities can occur and may be life-threatening.
Diagnosis involves a combination of clinical findings, laboratory testing, imaging, and confirmatory biopsy. Blood tests may show elevated lactate or creatine kinase, while electrocardiography is essential to detect cardiac involvement. Neuroimaging may reveal thin extraocular muscles or brain abnormalities. The gold standard for diagnosis is skeletal muscle biopsy demonstrating ragged-red fibers, representing accumulation of abnormal mitochondria. Genetic testing is increasingly used to confirm mutations.
Differential diagnosis includes other causes of ptosis and ophthalmoplegia such as Myasthenia gravis, congenital myopathies, and muscular dystrophies. Careful clinical evaluation and testing help distinguish these conditions.
There is no definitive cure for CPEO, and management is largely supportive. Surgical correction of ptosis may improve vision but must be approached cautiously due to poor eyelid closure and risk of exposure keratopathy. Strabismus surgery can help alleviate diplopia in selected patients. Systemic complications require targeted management, including pacemaker placement for cardiac conduction defects, endocrine therapy for metabolic disturbances, and antiepileptic treatment for seizures.
Adjunctive therapies such as vitamin supplementation (e.g., coenzyme Q10, vitamin B complex) are sometimes used, although evidence for their effectiveness is limited. Patients are advised to avoid mitochondrial stressors such as smoking and excessive alcohol consumption. Genetic counseling is important, particularly for families with inherited forms.
The prognosis is characterized by a slow, progressive course. While ocular motility continues to decline over time, life expectancy depends largely on the severity of systemic involvement, particularly cardiac complications.
Complications include cardiac conduction defects, endocrine dysfunction, progressive muscle weakness, and visual disability related to ptosis and ophthalmoplegia. Early recognition and multidisciplinary care are essential to reduce morbidity and prevent life-threatening complications.
- Published on
Ophthalmology – Canaliculitis
Canaliculitis is an acute or chronic inflammation of the lacrimal canalicular system, most often affecting the lower canaliculus. It is a relatively rare condition but occurs more frequently in adults and shows a strong female predominance (approximately 6:1). The condition is often underdiagnosed because it can mimic other causes of chronic red eye or discharge.
The underlying pathophysiology involves obstruction of the canaliculus, which leads to stagnation of tears and subsequent infection. Over time, this results in inflammation and the formation of concretions (dacryoliths) within the canaliculus. These concretions can harbor bacteria and make the infection persistent or recurrent.
The most common causative organisms include Streptococcus and Staphylococcus species, as well as Actinomyces and Propionibacterium. In many cases, infections are polymicrobial. Risk factors include prior placement of intracanalicular plugs, recurrent conjunctivitis, dacryocystitis, and chronic dry eye conditions.
Patients typically present with epiphora (excessive tearing), localized pain, and swelling near the punctum. A key feature is mucopurulent discharge, often expressed when pressure is applied over the canaliculus. On examination, the punctum may appear dilated and edematous, and the canaliculus is usually tender and erythematous. Slit-lamp examination often reveals discharge from the punctum and localized inflammation.
Diagnosis is largely clinical but can be supported by additional findings. Expression or probing of the canaliculus may yield concretions, which is highly diagnostic. Cultures and sensitivity testing can help guide antibiotic therapy, and fungal cultures may be considered in atypical cases. If the condition appears to extend beyond the canaliculus, imaging such as dacryocystography may be used to evaluate for deeper involvement or foreign bodies.
The differential diagnosis includes conditions such as dacryocystitis, chalazion, and mucopurulent conjunctivitis. Differentiation is important because treatment strategies differ significantly.
Initial treatment includes topical antibiotics, such as penicillin eye drops (100,000 units/mL) four times daily for two weeks, or sodium sulfacetamide if penicillin is unavailable. Warm compresses are also recommended to help reduce inflammation and promote drainage. However, medical therapy alone is often insufficient.
Definitive treatment typically requires a minor surgical procedure. Canaliculotomy, which involves making an incision into the canaliculus, allows for removal of all concretions. Complete removal is essential for cure, as retained material can lead to recurrence. Postoperatively, patients are usually treated with broad-spectrum antibiotic drops.
Prognosis is excellent, with nearly 100% cure rates when all concretions are removed. Complications are uncommon but may include recurrence if debris is not completely cleared, or, rarely, canalicular scarring leading to persistent tearing. Early recognition and appropriate management are key to preventing chronic symptoms and recurrence.
- Published on
Ophthalmology – Bullous Keratopathy
Bullous keratopathy is a corneal condition caused by endothelial failure, leading to chronic corneal edema and the formation of epithelial bullae (fluid-filled blisters). These bullae may rupture, resulting in episodes of significant ocular pain. The condition is most commonly seen after intraocular surgery, particularly cataract surgery, although its incidence has decreased with advances in surgical techniques and intraocular lens design. The risk is higher in complicated surgeries involving vitreous loss, anterior chamber lenses, or in patients with preexisting endothelial dysfunction such as Fuchs endothelial dystrophy.
The underlying pathophysiology involves progressive loss or dysfunction of corneal endothelial cells, which are responsible for maintaining corneal dehydration and clarity. As endothelial cells are lost, the remaining cells enlarge and become irregular in shape (polymegathism and pleomorphism). Eventually, the endothelial pump fails, leading to stromal swelling and fluid accumulation. This fluid extends into the epithelium, forming vesicles that may coalesce into bullae. When these bullae rupture, they expose corneal nerve endings, causing severe pain. Vision impairment is primarily due to epithelial edema, although stromal changes also contribute.
Patients typically present with gradually worsening blurred or “misty” vision, especially in the morning. This occurs because corneal edema worsens overnight due to reduced evaporation and decreased endothelial activity. Vision may improve as the day progresses, although this becomes less noticeable as the disease advances. Other symptoms include foreign body sensation, irritation, photophobia, tearing, and recurrent episodes of severe pain when bullae rupture.
On examination, the cornea appears dull and edematous. Slit-lamp findings include epithelial irregularities, superficial punctate keratitis, and bullae that may be intact (appearing as dark spots with fluorescein) or ruptured (staining brightly). Stromal edema presents as increased corneal thickness with fluid clefts, and folds in Descemet’s membrane may be visible. In advanced cases, corneal vascularization may develop. Associated findings may point to underlying causes, such as guttata in Fuchs dystrophy or signs of chronic uveitis or glaucoma.
Diagnostic evaluation may include specular microscopy, which demonstrates decreased endothelial cell density and abnormal cell morphology. Confocal microscopy can reveal epithelial bullae, stromal edema, and loss of corneal nerves. Pachymetry is useful in measuring corneal thickness; values greater than 590 μm in pseudophakic eyes suggest irreversible edema. These tools help assess severity and guide management.
Treatment focuses on symptom relief and, when possible, restoration of vision. Initial management includes hypertonic saline (5%) drops or ointment to reduce corneal edema, often used multiple times daily. Blowing warm air (such as from a hair dryer) across the eye can promote evaporation and reduce edema. Intraocular pressure should be controlled if elevated. For persistent symptoms, extended-wear soft contact lenses may be used to protect the corneal surface and reduce pain, although they carry risks such as infection and hypoxia.
Definitive treatment is corneal transplantation, either endothelial keratoplasty or penetrating keratoplasty, particularly in patients with visual potential. In patients who are not candidates for transplantation or lack visual potential, several palliative procedures may be considered. These include anterior stromal puncture to promote epithelial adherence, phototherapeutic keratectomy, and amniotic membrane transplantation to facilitate healing and reduce pain. In severe, painful cases without visual potential, more aggressive measures such as retrobulbar alcohol injection or even eye removal procedures may be required.
Complications of bullous keratopathy include corneal ulceration, secondary infection, scarring, vascularization, and reduced corneal sensitivity. The diseased epithelium is particularly vulnerable to infection, especially when protective measures like bandage contact lenses are used. Early recognition and appropriate management are essential to relieve symptoms and preserve vision where possible.
Bullous keratopathy is a corneal condition caused by endothelial failure, leading to chronic corneal edema and the formation of epithelial bullae (fluid-filled blisters). These bullae may rupture, resulting in episodes of significant ocular pain. The condition is most commonly seen after intraocular surgery, particularly cataract surgery, although its incidence has decreased with advances in surgical techniques and intraocular lens design. The risk is higher in complicated surgeries involving vitreous loss, anterior chamber lenses, or in patients with preexisting endothelial dysfunction such as Fuchs endothelial dystrophy.
The underlying pathophysiology involves progressive loss or dysfunction of corneal endothelial cells, which are responsible for maintaining corneal dehydration and clarity. As endothelial cells are lost, the remaining cells enlarge and become irregular in shape (polymegathism and pleomorphism). Eventually, the endothelial pump fails, leading to stromal swelling and fluid accumulation. This fluid extends into the epithelium, forming vesicles that may coalesce into bullae. When these bullae rupture, they expose corneal nerve endings, causing severe pain. Vision impairment is primarily due to epithelial edema, although stromal changes also contribute.
Patients typically present with gradually worsening blurred or “misty” vision, especially in the morning. This occurs because corneal edema worsens overnight due to reduced evaporation and decreased endothelial activity. Vision may improve as the day progresses, although this becomes less noticeable as the disease advances. Other symptoms include foreign body sensation, irritation, photophobia, tearing, and recurrent episodes of severe pain when bullae rupture.
On examination, the cornea appears dull and edematous. Slit-lamp findings include epithelial irregularities, superficial punctate keratitis, and bullae that may be intact (appearing as dark spots with fluorescein) or ruptured (staining brightly). Stromal edema presents as increased corneal thickness with fluid clefts, and folds in Descemet’s membrane may be visible. In advanced cases, corneal vascularization may develop. Associated findings may point to underlying causes, such as guttata in Fuchs dystrophy or signs of chronic uveitis or glaucoma.
Diagnostic evaluation may include specular microscopy, which demonstrates decreased endothelial cell density and abnormal cell morphology. Confocal microscopy can reveal epithelial bullae, stromal edema, and loss of corneal nerves. Pachymetry is useful in measuring corneal thickness; values greater than 590 μm in pseudophakic eyes suggest irreversible edema. These tools help assess severity and guide management.
Treatment focuses on symptom relief and, when possible, restoration of vision. Initial management includes hypertonic saline (5%) drops or ointment to reduce corneal edema, often used multiple times daily. Blowing warm air (such as from a hair dryer) across the eye can promote evaporation and reduce edema. Intraocular pressure should be controlled if elevated. For persistent symptoms, extended-wear soft contact lenses may be used to protect the corneal surface and reduce pain, although they carry risks such as infection and hypoxia.
Definitive treatment is corneal transplantation, either endothelial keratoplasty or penetrating keratoplasty, particularly in patients with visual potential. In patients who are not candidates for transplantation or lack visual potential, several palliative procedures may be considered. These include anterior stromal puncture to promote epithelial adherence, phototherapeutic keratectomy, and amniotic membrane transplantation to facilitate healing and reduce pain. In severe, painful cases without visual potential, more aggressive measures such as retrobulbar alcohol injection or even eye removal procedures may be required.
Complications of bullous keratopathy include corneal ulceration, secondary infection, scarring, vascularization, and reduced corneal sensitivity. The diseased epithelium is particularly vulnerable to infection, especially when protective measures like bandage contact lenses are used. Early recognition and appropriate management are essential to relieve symptoms and preserve vision where possible.
- Published on
Emergency and Acute Medicine – Torticollis
Torticollis, meaning “twisted neck,” is a clinical symptom rather than a disease entity. It refers to a fixed or dynamic abnormal posture of the head and neck, often involving rotation or tilting. It is also known as cervical dystonia or wry neck and may arise from a wide range of local or central causes.
The etiology of torticollis is broad and can be categorized into local and central causes. The most common form is acute wry neck, which typically develops अचानक (often overnight) without clear provocation and resolves spontaneously within 1–2 weeks. Local structural causes include cervical spine pathology such as fractures, dislocations, subluxations, spondylosis, tumors, ligamentous laxity (especially in the atlantoaxial region), and scar tissue from prior injury. Inflammatory or infectious causes include myositis, lymphadenitis, tuberculosis, and infections of surrounding tissues such as retropharyngeal abscess, meningitis, tonsillitis, mastoiditis, or sinusitis. Neurologic and neuromuscular causes include myasthenia gravis and neuritis. Compensatory torticollis may occur with ocular muscle palsy or head tremor.
Central causes include idiopathic spasmodic torticollis, which is more common in women aged 31–60 years, as well as dystonic disorders such as torsion dystonia, tardive dystonia from neuroleptic medications, Wilson disease, and toxic causes such as Strychnine poisoning. Drug-induced dystonia, particularly from antipsychotics, is a common acute cause and typically occurs within 12–23 hours of medication exposure.
In pediatric patients, causes include congenital abnormalities such as muscular torticollis due to sternocleidomastoid hypertrophy, vertebral anomalies, or syndromic conditions. Other causes include infections (e.g., otitis media, retropharyngeal abscess), trauma, gastroesophageal reflux, and central nervous system pathology such as posterior fossa tumors.
Clinically, patients present with intermittent or sustained painful spasms of the neck muscles, particularly the sternocleidomastoid and trapezius. The head is typically rotated and tilted to one side, with movements ranging from smooth deviation to jerking motions. Pure flexion (anterocollis) or extension (retrocollis) is uncommon. Symptoms are often exacerbated by activity, stress, or upright posture and typically resolve during sleep.
History should focus on recent trauma, medication exposure (especially antipsychotics), and systemic symptoms such as fever. On examination, the abnormal head posture is evident, and neurologic evaluation is essential. The presence of fever suggests an infectious cause, while focal neurologic deficits raise concern for central nervous system or spinal cord pathology. In congenital cases, a firm, nontender mass in the sternocleidomastoid muscle may be present.
Evaluation is directed at excluding serious causes. Cervical spine imaging is indicated when trauma is suspected. CT or MRI may be required if there is concern for abscess, tumor, or neurologic pathology. Ultrasound is the preferred modality for congenital muscular torticollis. No specific laboratory tests are routinely helpful.
Management depends on the underlying cause. Prehospital care includes ensuring airway patency, supporting the head, and maintaining cervical spine precautions if trauma is suspected. In the emergency setting, immobilization is essential when fracture is a concern.
For drug-induced torticollis, treatment with diphenhydramine or benztropine is highly effective. For non-drug-related cases, conservative management includes rest, soft cervical collar, physical therapy, massage, local heat, and analgesics. Benzodiazepines may be used for muscle relaxation. Botulinum toxin is the first-line treatment for chronic or non–drug-induced torticollis, although it is typically administered in an outpatient setting.
Patients require admission if there is suspicion of cervical spine fracture, infection, toxic appearance, inability to maintain hydration, or diagnostic uncertainty. Most uncomplicated cases can be managed as outpatients with referral to specialists such as neurologists, orthopedists, or neurosurgeons.
Key clinical pearls include always excluding serious causes such as infection (e.g., retropharyngeal abscess or meningitis), trauma, and central nervous system pathology before attributing symptoms to benign torticollis. Drug-induced dystonia is common and rapidly reversible with appropriate treatment, and failure to recognize life-threatening causes can lead to significant morbidity.
- Published on
Emergency and Acute Medicine – Toluene Poisoning
Toluene poisoning results from exposure to a volatile hydrocarbon that is a clear, colorless liquid with a characteristic sweet odor. It is widely used as an organic solvent in products such as paints, thinners, glues, inks, correction fluid, petroleum products, and aerosolized household items. Exposure may occur occupationally or through intentional abuse, particularly among adolescents due to its low cost and easy accessibility. Methods of abuse include sniffing directly from a container, huffing vapors from a soaked cloth, and bagging vapors in a confined space for inhalation.
Toluene is rapidly absorbed through inhalation and readily crosses the blood–brain barrier, achieving high concentrations in the brain. It exerts multiple toxic effects, including central nervous system depression, myocardial sensitization to catecholamines, and disruption of cardiac ion channels, predisposing to dangerous dysrhythmias. It is metabolized in the liver and excreted through the lungs and urine. Toxicity is dose-dependent, ranging from mild impairment at lower concentrations to anesthesia, seizures, and death at very high levels.
Clinically, acute toxicity primarily affects the neurologic, cardiac, pulmonary, and metabolic systems. Patients may present with euphoria, dizziness, ataxia, confusion, or seizures. Cardiac effects are particularly dangerous and include potentially fatal dysrhythmias, especially in the setting of catecholamine surges (“sudden sniffing death”). Pulmonary complications include chemical pneumonitis and pulmonary edema. Metabolic abnormalities are characteristic and include hypokalemia, hypocalcemia, and a hyperchloremic metabolic acidosis due to accumulation of hippuric acid. Gastrointestinal symptoms such as nausea, vomiting, and abdominal pain may occur, and renal effects include distal renal tubular acidosis, hematuria, and proteinuria.
Chronic exposure leads to progressive and often irreversible damage. Neurologic complications include peripheral neuropathy, leukoencephalopathy, cerebellar dysfunction, and cognitive impairment. Cardiac complications may include dilated cardiomyopathy and persistent dysrhythmias. Renal injury may progress to chronic failure, and musculoskeletal complications such as rhabdomyolysis can occur. Chronic abuse is also associated with psychiatric issues and addiction. In pregnancy, chronic exposure has been linked to fetal solvent syndrome, resembling fetal alcohol syndrome with growth restriction and developmental delay.
Diagnosis is primarily clinical, supported by history of exposure and physical findings such as solvent odor, perioral dermatitis, or evidence of inhalant use on clothing or skin. Laboratory evaluation typically reveals electrolyte abnormalities, particularly hypokalemia and metabolic acidosis. Renal function tests, creatine kinase (if rhabdomyolysis is suspected), and liver function tests should be obtained. Urinary hippuric acid may confirm exposure but does not correlate with severity. Imaging studies include ECG to detect dysrhythmias and chest radiography if respiratory symptoms are present.
Management focuses on supportive care and stabilization. Initial priorities include airway, breathing, and circulation, with supplemental oxygen, cardiac monitoring, and intravenous fluids. Sudden cardiac death is a major risk due to myocardial sensitization, so careful monitoring is essential. Dysrhythmias should be treated according to standard protocols, with consideration of β-blockers for tachydysrhythmias. Respiratory status should be monitored closely, and chemical pneumonitis is managed supportively, as steroids are not recommended.
Metabolic abnormalities should be corrected, including cautious repletion of potassium, calcium, and phosphate. Acidosis generally improves with fluid resuscitation. In cases of rhabdomyolysis, aggressive hydration is required to maintain urine output. Gastrointestinal decontamination is generally not useful and may increase the risk of aspiration; activated charcoal is ineffective for hydrocarbons.
Disposition depends on clinical severity. Patients with altered mental status, dysrhythmias, significant metabolic disturbances, renal failure, or rhabdomyolysis require admission. Those who return to baseline mental status and remain stable after 4–6 hours of observation without evidence of complications may be discharged.
Key clinical pearls include the risk of sudden death due to catecholamine-induced dysrhythmias and the importance of monitoring and correcting electrolyte abnormalities. Cardiac complications carry a poor prognosis, and cessation of exposure is the most important long-term intervention. Referral for psychiatric evaluation and substance abuse counseling is essential in cases of intentional or repeated use.
- Published on
Ophthalmology – Branch Retinal Vein Occlusion (BRVO)
Branch retinal vein occlusion (BRVO) is a retinal vascular disorder characterized by obstruction of blood flow in a branch retinal vein, typically at an arteriovenous crossing. It commonly presents with painless, variable vision loss, which may be blurred or distorted. Clinically, BRVO is classified into ischemic and nonischemic types, which differ in severity, prognosis, and risk of complications. It primarily affects individuals over 50 years of age, while pediatric cases are rare and often associated with identifiable systemic causes such as hypercoagulable states.
Epidemiologically, BRVO is the second most common retinal vascular disorder after diabetic retinopathy and is more common than central retinal vein occlusion. Its incidence increases with age, with a 15-year cumulative incidence of approximately 1.8% reported in population studies. The overall prevalence ranges from 0.6% to 1.6%, affecting both men and women equally.
The strongest risk factor for BRVO is systemic hypertension, present in the majority of patients. Other important risk factors include diabetes mellitus, hyperlipidemia, obesity, cardiovascular disease, and hyperviscosity syndromes. In younger patients, evaluation for thrombophilia or systemic disease is essential, as BRVO is less commonly idiopathic in this group.
Pathophysiologically, BRVO is believed to result from mechanical compression of a retinal vein by an adjacent artery at arteriovenous crossing points, where both share a common sheath. This leads to turbulent flow, endothelial injury, and thrombus formation—components of Virchow’s triad. The resulting venous obstruction causes increased hydrostatic pressure, retinal hemorrhage, and capillary leakage. Hypoxia stimulates increased production of vascular endothelial growth factor (VEGF), contributing to macular edema and neovascularization, which are major causes of vision loss.
Patients typically present with sudden or gradual vision loss, depending on the extent and location of involvement. Fundus examination reveals sectoral flame-shaped hemorrhages in the distribution of the affected vein, along with dilated and tortuous vessels. Additional findings may include cotton wool spots, microaneurysms, retinal edema, and, in chronic stages, collateral vessel formation and retinal pigment epithelial changes. The superotemporal quadrant is most commonly affected.
Diagnosis is primarily clinical, supported by imaging. Fluorescein angiography demonstrates delayed venous filling, leakage, and areas of capillary nonperfusion, particularly in ischemic BRVO (defined as greater than five disc areas of nonperfusion). Optical coherence tomography (OCT) is essential for detecting and monitoring macular edema. Laboratory investigations are generally unnecessary in older patients with known vascular risk factors but are important in younger patients to evaluate for systemic or hypercoagulable conditions.
Management focuses on treating complications such as macular edema and neovascularization. First-line therapy includes intravitreal anti-VEGF agents such as bevacizumab, ranibizumab, or dexamethasone implants, which reduce edema and improve visual outcomes. Historically, macular grid laser photocoagulation was used for persistent edema, and it remains an option in selected cases. Panretinal photocoagulation is indicated for neovascular complications but is not used prophylactically. In refractory cases, surgical options such as vitrectomy may be considered.
Patients require close follow-up, typically monthly for the first three months and then at regular intervals, with monitoring using OCT, fluorescein angiography, and visual field testing. Coordination with a primary care physician is important to manage systemic risk factors and prevent recurrence or progression.
The prognosis for BRVO is generally favorable, with about half of patients achieving visual acuity of 20/40 or better. However, outcomes vary depending on the extent of ischemia, presence of macular edema, and development of complications. Conversion from nonischemic to ischemic BRVO can occur, making prognosis unpredictable. Major complications include macular edema, macular ischemia, retinal neovascularization, and vitreous hemorrhage, all of which can significantly impact vision.
- Published on
Ophthalmology – Blind Baby
Blindness in infants is defined by the World Health Organization as a corrected visual acuity of 20/200 or worse in the better eye, or a visual field restricted to 10 degrees or less around central fixation. Childhood blindness is a significant global health issue, with marked variation depending on socioeconomic and environmental conditions. In developed countries, the incidence is approximately 0.3 per 1,000 children under five years, while globally it is higher, and an estimated 1.4 million children were blind worldwide as of 2000. Underprivileged regions bear a disproportionately higher burden due to preventable causes.
Risk factors for infant blindness span prenatal, perinatal, and childhood periods. Prenatal risks include genetic predisposition and maternal infections such as rubella, toxoplasmosis, cytomegalovirus, herpes simplex virus, and syphilis, as well as exposure to drugs or toxins. Prematurity is a major contributor in developed countries. Perinatal risks include hypoxia, infection, and trauma, while postnatal risks include malnutrition (especially vitamin A deficiency), infections, trauma, and systemic or neurological diseases. Genetic eye diseases and syndromic associations are among the leading causes overall.
The underlying mechanisms of blindness involve either structural abnormalities of the eye or visual pathways, or functional impairment such as amblyopia or cortical visual impairment. Causes may affect any part of the visual system, including the globe (e.g., anophthalmia, microphthalmia), cornea (opacities), lens (cataract), retina (retinopathy of prematurity, dystrophies), optic nerve (hypoplasia, atrophy), or brain (hypoxic injury, tumors, developmental anomalies). Associated systemic and infectious conditions are common, particularly congenital infections and syndromic disorders.
Diagnosis begins with careful history-taking, including family history of eye disease, maternal prenatal exposures, birth history, and developmental milestones. Clinically, infants may show signs such as poor eye contact, nystagmus, wandering eye movements, lack of fixation, or behaviors like eye poking (oculodigital sign). Examination includes assessment for structural abnormalities such as corneal opacity, cataract, retinal pathology, or optic nerve anomalies, as well as evaluation for systemic conditions.
Investigations are guided by suspected etiology. Imaging such as MRI may be used when optic nerve or cortical causes are suspected, while ocular ultrasound helps evaluate anatomy when media opacities are present. Electrophysiological testing can help assess retinal or cortical function when clinical findings are unclear. In some cases, examination under anesthesia is necessary for a complete assessment.
Management depends on the underlying cause but emphasizes early intervention. Treatable causes such as cataract, glaucoma, or retinopathy of prematurity require prompt surgical or medical treatment. Refractive errors should be corrected, and amblyopia therapy initiated when appropriate. Supportive care is crucial and includes low vision rehabilitation, mobility training, and individualized educational planning. Referral to specialists such as geneticists, pediatricians, and infectious disease experts is often required.
Prevention plays a major role, as up to half of childhood blindness is avoidable. Strategies include improving maternal health and prenatal care, preventing infections, reducing premature births, early screening for ocular conditions, and addressing nutritional deficiencies. Public health education and genetic counseling are also key components.
The prognosis varies widely depending on the cause and access to early diagnosis and treatment. With timely intervention and supportive care, many children can achieve improved functional vision and quality of life.
Ophthalmology – Blind Baby
Blindness in infants is defined by the World Health Organization as a corrected visual acuity of 20/200 or worse in the better eye, or a visual field restricted to 10 degrees or less around central fixation. Childhood blindness is a significant global health issue, with marked variation depending on socioeconomic and environmental conditions. In developed countries, the incidence is approximately 0.3 per 1,000 children under five years, while globally it is higher, and an estimated 1.4 million children were blind worldwide as of 2000. Underprivileged regions bear a disproportionately higher burden due to preventable causes.
Risk factors for infant blindness span prenatal, perinatal, and childhood periods. Prenatal risks include genetic predisposition and maternal infections such as rubella, toxoplasmosis, cytomegalovirus, herpes simplex virus, and syphilis, as well as exposure to drugs or toxins. Prematurity is a major contributor in developed countries. Perinatal risks include hypoxia, infection, and trauma, while postnatal risks include malnutrition (especially vitamin A deficiency), infections, trauma, and systemic or neurological diseases. Genetic eye diseases and syndromic associations are among the leading causes overall.
The underlying mechanisms of blindness involve either structural abnormalities of the eye or visual pathways, or functional impairment such as amblyopia or cortical visual impairment. Causes may affect any part of the visual system, including the globe (e.g., anophthalmia, microphthalmia), cornea (opacities), lens (cataract), retina (retinopathy of prematurity, dystrophies), optic nerve (hypoplasia, atrophy), or brain (hypoxic injury, tumors, developmental anomalies). Associated systemic and infectious conditions are common, particularly congenital infections and syndromic disorders.
Diagnosis begins with careful history-taking, including family history of eye disease, maternal prenatal exposures, birth history, and developmental milestones. Clinically, infants may show signs such as poor eye contact, nystagmus, wandering eye movements, lack of fixation, or behaviors like eye poking (oculodigital sign). Examination includes assessment for structural abnormalities such as corneal opacity, cataract, retinal pathology, or optic nerve anomalies, as well as evaluation for systemic conditions.
Investigations are guided by suspected etiology. Imaging such as MRI may be used when optic nerve or cortical causes are suspected, while ocular ultrasound helps evaluate anatomy when media opacities are present. Electrophysiological testing can help assess retinal or cortical function when clinical findings are unclear. In some cases, examination under anesthesia is necessary for a complete assessment.
Management depends on the underlying cause but emphasizes early intervention. Treatable causes such as cataract, glaucoma, or retinopathy of prematurity require prompt surgical or medical treatment. Refractive errors should be corrected, and amblyopia therapy initiated when appropriate. Supportive care is crucial and includes low vision rehabilitation, mobility training, and individualized educational planning. Referral to specialists such as geneticists, pediatricians, and infectious disease experts is often required.
Prevention plays a major role, as up to half of childhood blindness is avoidable. Strategies include improving maternal health and prenatal care, preventing infections, reducing premature births, early screening for ocular conditions, and addressing nutritional deficiencies. Public health education and genetic counseling are also key components.
The prognosis varies widely depending on the cause and access to early diagnosis and treatment. With timely intervention and supportive care, many children can achieve improved functional vision and quality of life.
